Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Sales are distributed by product family as follows:
- agrochemicals (45.5%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (41.2%) : intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc. ;
- OTC products and nutritional supplements (12.6%);
- other (0.7%).
Net sales are distributed geographically as follows: Germany (5.4%), Switzerland (1.2%), Europe-Middle East-Africa (23.7%), the United States (31.1%), North America (3.5%), China (8.6%), Asia-Pacific (11.2%), Brazil (8.1%) and Latin America (7.2%).
Number of employees : 103 824 people.
2019 EUR (in Million) % Crop Science 19,832 45.5% Pharmaceuticals 17,962 41.2% Consumer Health 5,462 12.5% All Other Segments 277.00 0.6% Corporate Functions and Consolidation 12.00 0%
2018 2019 Delta EUR (in Million) % EUR (in Million) % United States 9,793 24.7% 13,556 31.1% +38.43% Europe/Middle East/Africa 9,875 24.9% 10,315 23.7% +4.46% Asia/Pacific 5,188 13.1% 4,885 11.2% -5.84% China 2,927 7.4% 3,726 8.6% +27.3% Brazil 2,869 7.2% 3,539 8.1% +23.35% Latin America 2,890 7.3% 3,124 7.2% +8.1% Germany 3,819 9.6% 2,364 5.4% -38.1% North America 1,776 4.5% 1,531 3.5% -13.8% Switzerland 449.00 1.1% 505.00 1.2% +12.47%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
982,424,082
982,422,097
100.0% 0
0.0% 100.0%
Shareholders Bayer AG (DE000BAY0017) Bayer Aktiengesellschaft (US)
Name Equities % The Vanguard Group, Inc. 30,282,754
3.08% Norges Bank Investment Management 29,272,516
2.98% Harris Associates LP 27,902,083
2.84% Amundi Asset Management SA (Investment Management) 23,554,050
2.40% Fidelity Management & Research Co. LLC 18,483,532
1.88% Massachusetts Financial Services Co. 13,182,047
1.34% DWS Investments (UK) Ltd. 12,247,989
1.25% BlackRock Asset Management Deutschland AG 10,377,389
1.06% Dodge & Cox 9,342,392
0.95% DWS Investment GmbH 8,897,471
0.91%
Name Equities % Invesco Investment Advisers LLC 45,316,897
1.15% Fidelity Management & Research Co. LLC 15,934,078
0.41% Brandes Investment Partners LP 9,508,987
0.24% Cullen Capital Management LLC 5,159,888
0.13% Morgan Stanley Investment Management, Inc. 4,520,025
0.12% GLC Asset Management Group Ltd. 3,269,994
0.083% DG Capital Management Trust 3,234,991
0.082% Voya Investments LLC 2,640,408
0.067% Edge Asset Management, Inc. 2,549,783
0.065% Parametric Portfolio Associates LLC 2,318,253
0.059%
Name Equities % Valuation
Elanco Animal Health Incorporated (ELAN) 72,946,429 15.5% 2,037,393,762 USD Bayer CropScience Limited (506285) 25,344,917 56.4% 2,022,938,766 USD Covestro AG (1COV) 13,791,540 7.14% 684,911,598 USD Allakos Inc. (ALLK) 4,545,723 9.29% 370,249,138 USD CRISPR Therapeutics AG (CRSP) 2,954,775 4.21% 247,137,381 USD Evogene Ltd. (EVGN) 1,636,364 6.35% 7,133,352 USD
-
- Prime Standard
- DAX 30 / Euro Stoxx 50, FTSE Eurotop 100, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
- Bloomberg Code :
BAYGn:GR
- Reuters Code :
BAYGn.DE
- Datastream Code :
Company contact information
Bayer AG
Kaiser-Wilhelm Allee 1
DE-51368 Leverkusen, Nordrhein-Westfalen
Phone : +49 214 30 1
Fax :
Internet :
https://www.bayer.com/
Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion
Sector Pharmaceuticals - NEC
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
